Straits Times Index
3,283.73 +17.78 (+0.54%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,431.75 +50.40 (+0.60%) BTC-USD
63,040.27 +1,752.57 (+2.86%) CMC Crypto 200
1,303.72 -54.29 (-4.00%)
Takeda Pharmaceutical Company Limited (TAK)
Pre-market:
| Previous close | 13.06 |
| Open | 12.88 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 2900 |
| Day's range | 12.77 - 13.47 |
| 52-week range | 12.77 - 16.58 |
| Volume | |
| Avg. volume | 1,667,975 |
| Market cap | 41.955B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 46.10 |
| EPS (TTM) | 0.29 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 0.64 (4.77%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | 18.20 |
BenzingaJapan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio
Business WireTakeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.
GuruFocus.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
